Decorin as a multivalent therapeutic agent against cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Decorin is a small leucine-rich proteoglycan with diverse biological functions.
• It interacts with multiple receptor tyrosine kinases (RTKs) in the tumor microenvironment.
• The role of decorin in cancer, particularly in angiogenesis and tumor suppression, warrants further investigation.

Purpose of the Study:

• To elucidate the molecular mechanisms by which decorin exerts its anti-tumor effects.
• To investigate decorin's impact on endothelial cells, tumor cells, and immune cells within the tumor microenvironment.
• To evaluate decorin's therapeutic potential against solid malignancies.

Main Methods:

• In vitro and in vivo tumor models were utilized.
• Decorin's interactions with RTKs (e.g., VEGFR2, Met) were studied.
• Signaling pathways, including autophagy (Peg3/Beclin 1/LC3-dependent), were analyzed.
• Effects on endothelial cell migration, capillary morphogenesis, tumor cell growth, and macrophage function were assessed.

Main Results:

• Decorin binding to VEGFR2 in endothelial cells induced autophagy, inhibiting angiogenesis and endothelial cell migration.
• Decorin bound to RTKs like Met in tumor cells, promoting growth inhibition, mitophagy, and angiostasis.
• Decorin exhibited pro-inflammatory effects by modulating macrophage function and cytokine secretion.
• Decorin suppressed tumor growth, angiogenesis, and metastasis in various models.

Conclusions:

• Decorin possesses multifaceted oncosuppressive functions by targeting endothelial cells, tumor cells, and immune cells.
• Its ability to inhibit angiogenesis and tumor growth, coupled with its pro-inflammatory and immune-modulating properties, highlights its therapeutic promise.
• Decorin is a potent candidate for developing novel therapeutic strategies against solid tumors.